The University of Chicago Header Logo

Connection

Marina Chiara Garassino to Tubulin Modulators

Back to Details
This is a "connection" page, showing publications Marina Chiara Garassino has written about Tubulin Modulators.
Marina Chiara Garassino
Connection Strength
0.196
Tubulin Modulators
  1. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. J Clin Oncol. 2021 03 01; 39(7):723-733.
    View in: PubMed
    Score: 0.196
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.